FDA Special Protocol Assessment
||This article provides insufficient context for those unfamiliar with the subject. (December 2009)|
||This article may require cleanup to meet Wikipedia's quality standards. (December 2009)|
A Special Protocol Assessment (SPA) is a declaration from the Food and Drug Administration that an uncompleted Phase III trial's design, clinical endpoints, and statistical analyses are acceptable for FDA approval.
- animal carcinogenicity protocols,
- final product stability protocols,
- clinical protocols for phase 3 trials whose data will form the primary basis for an efficacy claim if the trials had been the subject of discussion at an end-of-phase 2/pre-phase 3 meeting with the review division, or in some cases, if the division agrees to such a review because the division is aware of the developmental context in which the protocol is being reviewed and the questions are being answered.
The clinical protocols for phase 3 trials can relate to efficacy claims that will be part of an original new drug application (NDA) or Biologic License Application (BLA) or that will be part of an efficacy supplement to an approved NDA or BLA.
PropThink hosts an active database  of companies with SPA agreements with the FDA.
|This medical article is a stub. You can help Wikipedia by expanding it.|